RTTNews | Oct 7, 2021 08:02AM EDT

08:02 Thursday, October 7, 2021 (RTTNews.com) - Recursion (RXRX) said that the U.S. Food and Drug Administration has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas.

REC-2282 is a orally bioavailable, CNS-penetrant small molecule HDAC inhibitor being developed for the treatment of NF2-mutated meningiomas.

The FDA's Fast Track designation was established to expedite the review of investigational drugs to treat serious conditions and address unmet medical needs by enabling important drugs to get to patients earlier if approved.

Meningiomas are primary tumors of the meninges of the central nervous system. More than 34,000 patients are diagnosed with sporadic meningiomas in the US each year. In patients with progressive meningiomas, more than a third are driven by mutations in the gene NF2.

Read the original article on RTTNews ( https://www.rttnews.com/3231147/recursion-s-rec-2282-granted-fda-fast-track-designation-for-nf2-mutated-meningiomas-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved